生脉注射液联合泼尼松和环磷酰胺治疗膜性肾病的临床研究

目的 探讨生脉注射液联合泼尼松和环磷酰胺治疗膜性肾病的临床疗效.方法 选择2017年6月—2020年6月上海市第六人民医院金山分院收治的53例膜性肾病的患者,随机分为对照组(25例)和治疗组(28例).对照组口服泼尼松片,1 mg/kg,1次/d,8周后每2周减量5 mg,减至30 mg/d,再每2周减量2.5 mg,...

Clinical study on Shengmai Injection combined with prednisone and cyclophosphamide in treatment of membranous nephropathy

Objective To investigate the effect of Shengmai Injection combined with prednisone and cyclophosphamide in treatment of membranous nephropathy. Methods Patients (53 cases) with membranous nephropathy in Jinshan Branch of Shanghai the 6th People''s Hospital from June 2017 to June 2020 were randomly divided into control (25 cases) and treatment (28 cases) groups. Patients in the control group were po administered with Prednisone Tablets, 1 mg/kg, once daily, reduced 5 mg every 2 weeks to 30 mg/d after 8 weeks, then reduced 2.5 mg every 2 weeks to 20 mg/d, and then reduced 2.5 mg every 4 weeks to 10 mg/d and maintained. At the same time, the control group iv administered with Cyclophosphamide for injection, 600 mg added into 100 mL normal saline in the first month, and then 800 mg added into 100 mL normal saline every month, once monthly, they were treated for 6 months. Patients in the treatment group were iv administered with Shengmai Injection, 40 mL added into 250 mL normal saline, once daily, 14 days of treatment and 16 days of withdrawal was a course of treatment for a total of 6 courses. After treatment, the clinical efficacy was evaluated, the levels of 24 h Upro, PCT and CRP in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 78.57%, which was significantly higher than 64.00% of the control group (P<0.05). After 3 and 6 months of treatment, the 24 h Upro level in two groups was significantly decreased, but PCT and CRP were increased (P<0.05). The 24 h Upro, PCT and CRP levels in the treatment group were lower than those in the control group (P<0.05). Conclusion Shengmai Injection combined with glucocorticoid and cyclophosphamide can improve the clinical curative effect and reduce the degree of inflammatory reaction.